AHLi-11

N/A

Report date: 2024/12/02 11:05:56
NME

Base Information

Drug NameAHLi-11
Drug Alias NameQP-HL1QP-HL2QP-HL3
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionTumor protein p53 inhibitors
TargetsTumor protein p53
Therapy Area/IndicationsMeniere DiseaseHearing Loss, Noise-InducedHearing Loss, Sensorineural +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesQuark Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesQuark Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsMeniere DiseaseHearing Disorders
Inactive IndicationsHearing Loss, Noise-InducedHearing Loss, Sensorineural

Other Information

ATC CodeN/A
Related LinksN/A